Olivier Cussenot

Germline polygenic score for prostate cancer aggressiveness

This paper develops a germline polygenic score (PRSagg) to predict prostate cancer aggressiveness and validates it across multiple datasets.

From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study

The paper develops a polygenic risk model for prostate cancer using VA data and validates it in external cohorts, showing its clinical utility in risk stratification.

Clonal phylogenies inferred from bulk, single cell, and spatial transcriptomic analysis of cancer

The paper evaluates the accuracy of transcript-based inferred tumor phylogenies compared to DNA-based phylogenies in prostate cancer using single-cell, spatial transcriptomic, and bulk data.

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of heterogeneity on genomic signature scoring

The paper uses spatial transcriptomic data to show that bulk genomic signature scoring in prostate cancer biopsies is confounded by tumour heterogeneity, leading to inaccurate risk assessments.

Prostate cancer risk stratification improved across multiple ancestries with new polygenic hazard score

The paper improves prostate cancer risk stratification across multiple ancestries using a new polygenic hazard score with additional SNPs, showing higher hazard ratios and positive predictive value for clinically significant prostate cancer.

Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24

The paper assesses how the performance of an African-ancestry-specific polygenic hazard score varies with local ancestry in 8q24 using genetic data from 6,253 men with African ancestry.

Polygenic hazard score is associated with prostate cancer in multi-ethnic populations

This study evaluates a polygenic hazard score in multi-ethnic populations and finds it is associated with age at prostate cancer diagnosis, aggressive diagnosis, and death across European, Asian, and African ancestries.

Additional SNPs improve the performance of a polygenic hazard score for prostate cancer

This study improves a polygenic hazard score for prostate cancer by adding 120 SNPs, enhancing hazard ratios but not positive predictive value of PSA testing.

African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer

The paper improves a polygenic hazard score for prostate cancer age at diagnosis by adding SNPs specific to African ancestry, enhancing performance in this population.